Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

BMJ publishes 'transparency scorecard'

November 13, 2015 2:44 AM UTC

In a GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) and Johnson & Johnson (NYSE:JNJ) reported results from 100% of clinical trials.

According to the paper, Gilead Sciences Inc. (NASDAQ:GILD) was the least transparent, publicly reporting results from 21% of trials that supported approval of Stribild elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article